Genetic Technologies Limited has emerged from voluntary administration following a strategic asset sale and is now pursuing recapitalisation and acquisitions to restore its market position.
Genetic Technologies Limited reports a 36% increase in half-year losses amid voluntary administration, followed by a recapitalisation and sale of core assets. The company pivots towards new financial services acquisitions under fresh leadership.
Genetic Technologies Limited has signed binding term sheets to acquire Ellerfield Wealth and Walker Capital, marking a strategic shift into wealth management backed by a $7.8 million valuation and pending ASX approvals.
Genetic Technologies Limited has announced significant leadership changes, appointing Michael Walker as Executive Chairman and Managing Director, alongside new executive and board members.
Genetic Technologies Limited has officially exited external administration following the effectuation of a Deed of Company Arrangement, marking a significant shift in its corporate governance and creditor relations.